As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > BUSINESS
BUSINESS
- Prices Should Remain Stable in 2nd-Half: Pres. Ishiguro of Alfresa HD
November 8, 2011
- Kyorin HD: Both Sales, Profits Remain Virtually Unchanged
November 8, 2011
- Eli Lilly, Amylin to Terminate Collaboration in Field of Diabetes
November 8, 2011
- Kobayashi Pharm. to Create 3 Subsidiaries in Southeast Asia
November 8, 2011
- Takeda Establishes New Positions in R&D, Global Sales
November 7, 2011
- Takeda Reinstates Request for Probe into Transfer Pricing Taxation
November 7, 2011
- Takeda: Sales, Profits Down due to Strong Yen, Double-digit Decreases in Sales of Actos in Apr-Sep
November 7, 2011
- Suzuken Reports Largest Interim Operating Loss From Drug Wholesale Business
November 7, 2011
- Operating Profits Down 70% in Wholesale Business: Alfresa HD
November 7, 2011
- 8 of 10 Leading Drug Makers Report Declines in 1st-Half Sales
November 7, 2011
- Takeda President Hasegawa Plans to Complete Integration with Nycomed in 3 Years
November 7, 2011
- Ono: Glactiv, Emend Drive Growth in 1st-Half Sales
November 7, 2011
- Astellas President Hatanaka Says Company Can Continue on Growth Path Through 2014
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…